BBG setbacks for 2 compounds

British Biotech (LSE:BBG; BBIOY) said it stopped a Phase II trial of E21R to treat acute myeloid leukemia (AML) after new preclinical data did not support a

Read the full 277 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE